HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (NASDAQ:ARDM) (the "Company") today
announced financial results for the fourth quarter and full year ended
December 31, 2014.
Fourth Quarter 2014 Results
The Company recorded $8.1 million in revenue in the fourth quart...

HAYWARD, CA -- (Marketwired) -- 02/27/15 --
Aradigm Corporation (NASDAQ: ARDM), a company actively engaged in fulfilling the promise of developing inhalation drug products that could revolutionize the quality of life of patients with severe pulmonary disease, announced today that President and Chief Executive Officer (CEO) Dr. Igor Gonda, Ph.D....

HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (Nasdaq:ARDM) (the "Company") today announced that
President and Chief Executive Officer, Igor Gonda, Ph.D., will present
at the 17th Annual BIO CEO & Investor Conference 2015 on
Tuesday, February 10, 2015, at 2:30 p.m. ET. The event will be held at
...

HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (Nasdaq:ARDM) (the "Company") today
announced that the European Patent Office has issued an important new
composition of matter patent entitled "Dual Action, Inhaled Formulations
Providing Both an Immediate and Sustained Release Profile," (E.U. Patent
...

HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (Nasdaq:ARDM) (the "Company") today announced that
President and Chief Executive Officer, Igor Gonda, Ph.D., will present
an overview of the Company at Biotech Showcase 2015 on Wednesday,
January 14, 2015, at 2:30 p.m. Pacific time. The event will be held at
...

HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (Nasdaq:ARDM) (the "Company") today announced
that Igor Gonda, Aradigm's President and Chief Executive Officer, will
present an overview of the Company at the Stifel Healthcare Conference
2014 at the New York Palace Hotel in New York, New York on Tuesday,
...

HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (Nasdaq:ARDM) (the "Company") today
announced financial results for the third quarter and nine months ended
September 30, 2014.
Total revenue was approximately $6.6 million for the third quarter of
2014 compared with revenue of approx...

NASDAQ listing achieved upon completion of reverse split
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (Nasdaq:ARDM) (the "Company") today
announced financial results for the second quarter and six months ended
June 30, 2014.
Total revenue was $12.2 million ...

HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (Nasdaq:ARDM) (the "Company") will host a corporate
update conference call at 8:00 am ET (5:00 am PT) on Thursday, June 26,
2014.
The Company will review recent significant milestones, as well as
progress with the Pulmaquin® prog...

Aradigm's Pulmaquin - A Potential New Therapy to Treat an Unmet
Medical Need in Patients with Severe Respiratory Disease
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (Nasdaq:ARDM) ("Aradigm" or the "Company") today
announced the dosing of the first patient in the ORBIT-4 (Once-dail...

HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTC BB:ARDM.OB) ("Aradigm" or the "Company")
announced that it has received the $5 million milestone payment from
Grifols S.A. for the dosing of the first patient in the ORBIT-3 (Once-daily
Respiratory Bronchiectasis
Inhalation Treatment)
P...

Completion of Royalty Assignment Eliminates All Debt
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTC BB: ARDM.OB) (the "Company") today
announced financial results for the first quarter and three months ended
March 31, 2014.
Total revenue was $6.6 million...

Aradigm's Pulmaquin - A Potential New Therapy to Treat an Unmet
Medical Need in Patients with Severe Respiratory Disease
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB:ARDM.OB) ("Aradigm" or the "Company")
today announced the dosing of the first patient in the ORBIT-3 (Once-da...

HAYWARD, Calif.--(BUSINESS WIRE)--
Scientists from the Oregon State University, Corvallis (OSU) and Aradigm
Corporation (OTCBB: ARDM) (the "Company") demonstrated that after 4 days
of in vitro treatment of macrophages infected with Mycobacterium avium
and Mycobacterium abscessus, Aradigm's liposomal ciprofloxacin...

HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTC BB: ARDM.OB) (the "Company") today
announced financial results for the fourth quarter and full year ended
December 31, 2013.
Fourth Quarter 2013 Results
The Company recorded $4.6 million in revenue in the fourth q...

HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that
President and Chief Executive Officer, Igor Gonda, Ph.D., will present
at the 16th Annual BIO CEO & Investor Conference 2014 on
Tuesday, February 11, 2014, at 10:30 a.m. ET. The event will be held at
...